Generate Biomedicines Inc (NASDAQ:GENB) Given Average Recommendation of “Moderate Buy” by Analysts

Generate Biomedicines Inc (NASDAQ:GENB) has received a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $25.40.

Several research analysts have weighed in on GENB shares. The Goldman Sachs Group started coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They issued a “buy” rating and a $26.00 price target for the company. Wall Street Zen downgraded Generate Biomedicines from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Guggenheim started coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They issued a “buy” rating and a $30.00 price target for the company. Piper Sandler started coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They issued an “overweight” rating and a $24.00 price target for the company. Finally, Cantor Fitzgerald started coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They issued an “overweight” rating for the company.

Generate Biomedicines Stock Down 12.4%

Shares of NASDAQ:GENB opened at $12.87 on Friday. The company’s 50 day moving average is $13.19. Generate Biomedicines has a 12-month low of $11.00 and a 12-month high of $16.75.

Generate Biomedicines (NASDAQ:GENB) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.59).

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.